Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti-pseudomonal β-lactam: Does "S" equal success in the presence of resistance to other anti-pseudomonal β-lactams?

被引:3
|
作者
Lodise, Thomas P. [1 ]
Puzniak, Laura A. [2 ]
Chen, Lie H. [3 ]
Tian, Yun [3 ]
Wei, Rong [3 ]
Im, Theresa M. [3 ]
Tartof, Sara Y. [3 ]
机构
[1] Abany Coll Pharm Hlth Sci, Dept Pharm Practice, Albany, NY 12208 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Sch Med, Pasadena, CA 91101 USA
来源
PHARMACOTHERAPY | 2021年 / 41卷 / 08期
关键词
antibiotics; beta-lactams; epidemiology; outcomes; pseudomonas; resistance; treatment; ANTIMICROBIAL RESISTANCE; 30-DAY MORTALITY; INFECTIONS; IMPACT; RISK; GUIDELINES; MANAGEMENT; SOCIETY;
D O I
10.1002/phar.2600
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objectives The most commonly prescribed antibiotics for patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) due to Pseudomonas aeruginosa are the conventional anti-pseudomonal beta-lactams (APBLs) (ie, ceftazidime, cefepime, meropenem, or piperacillin-tazobactam). Similar resistance mechanisms in P. aeruginosa affect the APBLs, and it is unclear if resistance to one APBL can affect the effectiveness of other APBLs. This exploratory, hypothesis-generating analysis evaluates the impact of APBL resistance among patients in the intensive care unit (ICU) with P. aeruginosa HABP/VABP who initially receive a microbiologically active APBL. Design A retrospective cohort [GJ1] [LT2] study. Setting Kaiser Permanente Southern California members (01/01/2011-12/31/2017). Patients The study included adult patients admitted to the ICU with a monomicrobial P. aeruginosa HABP/VABP who received a microbiologically active APBL within 2 days of index P. aeruginosa respiratory culture. Intervention Patients were stratified by presence of resistance to APBL on index P. aeruginosa (0 vs. >= 1 resistant APBL). Measurements Primary outcomes were 30-day mortality and discharge to home. Main Results Overall, 553 patients were included. Thirty-day mortality was 28%, and 32% of patients were discharged home. Eighty-eight patients (16%) had a P. aeruginosa HABP/VABP that was resistant to >= 1 APBL (other than active empiric treatment). Relative to patients with no APBL resistance, patients with resistance to >= 1 APBL had a higher 30-day mortality (adjusted odds ratio (aOR) [95% confidence interval (CI)]: 1.65 [1.02-2.66]) and were less likely to be discharged home (adjusted hazard ratio (aHR) [95% CI]: 0.50 [0.29-0.85]). Conclusion Further study is needed, but this exploratory analysis suggests that the full APBL susceptibility profile should be considered when selecting therapy for patients with P. aeruginosa HABP/VABP.
引用
收藏
页码:658 / 667
页数:10
相关论文
共 2 条
  • [1] Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumonia
    Pascual Guardia, Sergi
    Marin Corral, Judith
    Amati, Francesco
    Aliberti, Stefano
    Gea, Joaquim
    Soni, Nilam J.
    Rodriguez, Alejandro
    Sibila, Oriol
    Sanz, Francisco
    Sotgiu, Giovanni
    Marcos, Pedro J.
    Kolditz, Martin
    Antonio, Anzueto
    Restrepo, Marcos, I
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [2] EFFECTS OF INHALED MP-376 (AEROQUIN, LEVOFLOXACIN INHALATION SOLUTION) ON THE NEED FOR OTHER ANTI-PSEUDOMONAL ANTIMICROBIALS IN STABLE CF PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA LUNG INFECTION
    Geller, D.
    Flume, P. A.
    Sindel, L.
    Staab, D.
    Fischer, R.
    Loutit, J.
    Conrad, D.
    [J]. PEDIATRIC PULMONOLOGY, 2010, : 301 - 302